Pelzer U, et al. - In patients with advanced pancreatic carcinoma (APC) and cholestatic hyperbilirubinaemia, researchers examined the safety and effectiveness of nanoparticle albumin–bound paclitaxel and gemcitabine (nab-P/G). For this retrospective study, they screened their prospective database for patients with APC treated with nab-P/G at total bilirubin levels of ≥ 1.2 mg/dl. In patients with cholestasis and hyperbilirubinaemia, no unexpected toxicity of nab-P/G was noted. Findings revealed that individualized dose administration of nab-P/G in patients with cholestatic hyperbilirubinaemia with APC was feasible and safe.